



Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, the progress of regulatory submissions and approvals and subsequent commercialization and the potential use of Syndax's product candidates to treat various cancer indications and fibrotic diseases, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical site activation rates or clinical trial enrollment rates that are lower than expected; changes in expected or existing competition; the impact of macroeconomic conditions (the Russia-Ukraine war, inflation, among others) on Syndax's business and that of the third parties on which Syndax depends, including delaying or otherwise disrupting Syndax's clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.



Building
momentum in
2024 off an
impactful 4Q23

Recent Accomplishments



Presented positive **revumenib** and **axatilimab** data @ ASH 2023: *AGAVE-201, AUGMENT-101, SAVE, BEAT AML and AUGMENT-102*



Completed **revumenib** NDA submission under RTOR for R/R KMT2Ar acute leukemia; expect to receive a PDUFA action data in 1Q24



Granted priority review and a PDUFA action date of August 28, 2024, for **axatilimab** BLA filing in refractory chronic GVHD



Strengthened cash balance by \$258 million in 4Q23




Initiated Phase 2 idiopathic pulmonary fibrosis trial with **axatilimab**



Initiated **revumenib** Phase 1 combination trial with 7+3 chemotherapy in newly diagnosed mNPM1 or KMT2Ar acute leukemias

Revumenib KMT2Ar pivotal data establishes compelling clinical activity across acute leukemia patients; drives durable, MRD^{neg} responses



Enables a high rate of deep, durable MRD^{neg} responses in late line R/R patients

Responses observed across all major subgroups

Favorable safety and tolerability profile with low 6% treatment discontinuations due to TRAEs

Revumenib creates potential new opportunities for patients – enabling a meaningful shift in the treatment of R/R KMT2Ar acute leukemia

Anticipated KMT2Ar treatment paradigm pending approval of revumenib



Relapsed or Refractory
(n = 57)



Revumenib

HSCT

Revumenib maintenance

63%
respond
(36/57)

39%
receive
transplant[^]

71%
received or eligible
for post-transplant
maintenance*
(10/14)

Revumenib induces MRD^{neg} complete response, supports high rates of stem cell transplant and long-term post-transplant maintenance

[^] 8 of 14 patients went to transplant without achieving a CR or CRh

* 7 patients received post-transplant maintenance, 3 remained eligible to choose post-transplant maintenance as of data cut

mNPM1 AML Phase 1 results suggest robust efficacy with durable, MRD^{neg} responses

Phase 1 Dose Escalation	
	n (%)
Total mNPM1 @ RP2D	14
CR/CRh	5 (36%)
MRD ^{neg} CR/CRh	5 (100%)
ORR	7 (50%)

No treatment related discontinuations
 No grade 4 or 5 QTc events
 Only differentiation syndrome ≤ grade 2 observed

3/7 (43%) of responders proceeded to HSCT

1 patient restarted revumenib post HSCT*

3/5 patients achieving CR/CRh maintained response beyond 6 months, 2 for >22 months


TRAEs in-line with overall AUGMENT-101 Phase 1/2 experience

mNPM1 enrollment in AUGMENT-101 expected to complete in late 1Q/early 2Q

* Data cutoff of July 24, 2023; 2023 amendment allowed patients to restart treatment with revumenib post-transplant following HSCT; mNPM1, Mutated nucleophosmin; HSCT, Haematopoietic stem cell transplant; RP2D, Doses that met exposure equivalent of 226 mg q12h or 276mg q12h without strong CYP3A4 inhibitor or 113 mg q12h or 163 mg q12h with strong CYP3A4 inhibitor

Revumenib could provide significant benefit in mNPM1 and KMT2Ar acute leukemias across the treatment paradigm

mNPM1 & KMT2Ar acute leukemia treatment paradigm



Revumenib clinical development program (KMT2Ar and mNPM1 acute leukemia) - ongoing trials

Pivotal

AUGMENT-101
Rev Monotherapy

Phase 1/2

BEAT AML
Rev + Ven/Aza

INTERCEPT
Rev Monotherapy Tx

AUGMENT-102
Rev + Chemo

Rev + Intensive Chemo "7+3"

Maintenance

SAVE
Rev + Ven + INQOVI®

BEAT AML: Ven/Aza + revumenib in frontline mNPM1 or KMT2Ar AML

Summary of Enrolled Patients & Response Data

n = 13

Total enrolled

KMT2Ar: 5
mNPM1: 8

Response and Transplant

CRc 13 (100%)

CR/CRh 11 (85%)

CRi 2 (15%)

Transplant 2

Relapse 1

MRD Flow Status

MRD^{neg} 12 (92%)

Unknown MRD status 1 (8%)

Safety Summary

- No increased safety issues outside of known reported ven/aza toxicities
- Only 1 DLT (113 mg q12 h) observed
- No increase in cytopenias beyond ven/aza doublet

Trial expanding to validate RP2D – additional data expected in 2H24

SAVE AML: Ven/HMA combo in relapsed mNPM1, NUP98r or KMT2Ar AML/MPAL

Summary of Enrolled Patients & Response Data		
	N (%)	Subtype
Total enrolled	9	KMT2Ar: 5; mNPM1: 1 NUP98r: 2
Median prior Tx	3	56% received prior ven 67% received prior HSCT
Best response		
ORR	9 (100%)	KMT2Ar + NUP98r + mNPM1
CRc	7 (78%)	KMT2Ar + NUP98r + mNPM1
CR	3 (33%)	KMT2Ar (3)*
CRh	1 (11%)	NUP98r (1)*
CRp	3 (33%)	mNPM1 (1)* + KMT2Ar (2)*
CRc MRD^{neg}	6/7 (86%)	KMT2Ar (4), mNPM1 (1), NUP98r (1)
MLFS	1 (11%)	NUP98r (1)
PR	1 (11%)	NUP98r (1)


Safety Summary

- No discontinuations for TRAEs
- No \geq Gr 3 QTc
- No new or increased safety signals observed beyond ven/HMA

Trial expanding to validate RP2D; additional data expected in 2H24

Revumenib's profile supports use as backbone therapy across treatment continuum – providing access to >\$4B US market opportunity

Significant growth potential with indications in earlier lines of treatment



AGAVE-201 results support axatilimab's promising safety and efficacy profile

BLA Filing granted Priority Review by the FDA with a PDUFA action date of August 28, 2024

74%

ORR by cycle 7 day 1
(95% CI [63, 83])

60%

of responders maintained
a response at 1 year

55%

of patients had a ≥ 7 point
decrease in mLSS

Met the primary endpoint in patients
with R/R chronic GVHD


Durable responses with a reduction in
symptom burden

Well-tolerated, and the most common
adverse events were consistent with on-
target effects and prior trials

Complete responses were observed across all organ system, and across patients with prior exposure to approved agents including ibrutinib, ruxolitinib, and/or belumosudil

Organ responses in 0.3 mg/kg Q2W



>85% of patients reported a reduction in chronic GVHD-related symptom burden



Responses notable in fibrosis-dominated organs, including esophagus (78%), joints/fascia (76%), lung (47%), and skin (27%)


Anti-fibrotic effects of CSF-1R blockade extends to lung fibrosis

Preclinical data indicates CSF-1R inhibition prevents pulmonary fibrosis by depletion of interstitial macrophages



Ab535 is a mouse specific anti-CSF-1R antibody

Axatilimab Phase 1/2 trial data in patients with bronchiolitis obliterans syndrome




Left: Intra-tracheal bleomycin model; Ab535 - (UCB patent application WO2015028454 2. Histopathological Fibrosis Score; 3. Alexander et al. J Clin Invest. 2014;10:4266-4680;

Right: Radojic V. presentation at ATS, May 19 - 24, 2024. FEV1, forced expiratory volume in 1 second. Baseline defined as the latter FEV1 assessment at screening and C1D1 except for 1 subject, baseline is the FEV1 assessment at C1D15. Percent change in FEV1 from baseline is shown for 9 patients; 1 additional patient did not show a progression as reported by change in volume (liters). FEV1 monitoring not mandated by protocol

Axatilimab Phase 2 trial in IPF trial now enrolling patients


A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)



Axatilimab's advancement into IPF supported by:

- Published preclinical and clinical rationale for CSF-1 pathway inhibition in IPF
- Clinical results from chronic GVHD trials showing the positive impact on lung fibrosis

Axatilimab has the potential to expand into additional high value indications and new geographies



Financial highlights and financial guidance

Ticker	SNDX (NASDAQ)	
Cash and equivalents [†] (31 December 2023)	\$600.5 M	
Shares outstanding* (31 December 2023)	85.1 M	
2024 Operating Expense Guidance		
	1Q24	FY24
Research and development	\$56 - \$62 M	\$240 - \$260 M
Total operating expenses [^]	\$82 - \$88 M	\$355 - \$375 M

* Includes pre-funded warrants to purchase 285,714 common shares (rounded)

[^] Includes an estimated \$43 million in non-cash stock compensation expense for the full year 2024

[†] Includes short- and long-term investments



Expected upcoming clinical milestones

REVUMENIB

Menin-KMT2A disruption

- Approval and launch in R/R KMT2Ar acute leukemia in 2024
- Complete pivotal mNPM1 enrollment in late 1Q24/early 2Q24; data in 4Q24
- Update from Phase 1 metastatic CRC trial in 2Q24
- Additional data from revumenib Phase 1 combination studies (BEAT-AML, SAVE and AUGMENT-102) in 2H24
- Initiation of pivotal combination trial with ven/aza in frontline mNPM1 or KMT2Ar acute leukemias by YE24

AXATILIMAB

Anti-CSF-1R

- Approval and launch in refractory chronic GVHD in 2024
- Initiation of frontline combination trial with Jakafi® in mid-24
- Initiation of frontline combination trial with steroids in mid-24

